Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
0.7290
-0.0187 (-2.50%)
At close: Oct 14, 2026, 4:00 PM EDT
0.7100
-0.0190 (-2.61%)
Pre-market: Oct 15, 2026, 6:02 AM EDT
Daré Bioscience Employees
As of December 31, 2025, Daré Bioscience had 24 total employees, including 21 full-time and 3 part-time employees. The number of employees increased by 1 or 4.35% compared to the previous year. That makes Daré Bioscience the 37,762nd largest employer in the world and 5,384th in the United States.
Employees
24
Change (1Y)
1
Growth (1Y)
4.35%
Revenue / Employee
$56,914
Profits / Employee
-$457,798
Market Cap
14.34M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 24 | 1 | 4.35% | 21 | 3 |
| Dec 31, 2024 | 23 | -3 | -11.54% | 21 | 2 |
| Dec 31, 2023 | 26 | -4 | -13.33% | 23 | 3 |
| Dec 31, 2022 | 30 | 2 | 7.14% | 25 | 5 |
| Dec 31, 2021 | 28 | 5 | 21.74% | 20 | 8 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| Palatin Technologies | 25 |
| BioCardia | 21 |
| Radiopharm Theranostics | 14 |
| Cellectar Biosciences | 11 |
| Allarity Therapeutics | 8 |
| Dyadic International | 5 |
| Pasithea Therapeutics | 5 |
DARE News
- 1 day ago - Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities - GlobeNewsWire
- 6 days ago - Dare Bioscience to present Sildenafil Cream data at SMSNA meeting - TheFly
- 8 days ago - Daré Bioscience Proxy statement: Proxy filing - Filings
- 16 days ago - Dare Bioscience announces issuance of patent for DARE-HPV program - TheFly
- 16 days ago - Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection - GlobeNewsWire
- 21 days ago - Daré Bioscience Proxy statement: Proxy filing - Filings
- 4 weeks ago - Dare Bioscience publishes results from Sildenafil Cream study - TheFly
- 4 weeks ago - Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil - GlobeNewsWire